ADHD and Sleep

• Sleep problems occur in up to half of children with ADHD, and are reported at up to fivefold higher rates than in healthy controls — Kaplan & Sadock's Comprehensive Textbook of Psychiatry
• Common sleep complaints include difficulty settling to sleep, greater variation in sleep-onset time, bedtime struggles, and longer total sleep duration
• Children with ADHD have a higher prevalence of sleep-disordered breathing (SDB), periodic limb movement disorder (PLMD), and habitual snoring (3x more common than controls)
• Circadian rhythm abnormalities are frequent, with delayed dim-light melatonin onset contributing to sleep-onset insomnia
• Crucially, sleep restriction in otherwise healthy children can itself produce ADHD-like symptoms — inattention, hyperactivity, impulsivity, and poor cognitive performance — creating a bidirectional relationship

Managing Sleep in ADHD

Lemborexant: Mechanism and Profile

Mechanism

Key Pharmacology

Advantages Over Benzodiazepines / Z-drugs

Lemborexant in ADHD Context

• ADHD stimulant medications (methylphenidate, amphetamine) work partly by activating dopamine pathways that downstream trigger orexin release to stabilize wakefulness — this is the mechanism for their pro-wakefulness effects. — Stahl's
• A DORA like lemborexant could theoretically address stimulant-driven insomnia by blocking orexin-mediated wake-promotion without the amnesia and dependence risks of benzodiazepines or Z-drugs.
• Current evidence-based adjunctive choices for ADHD sleep remain melatonin and clonidine; lemborexant would be considered off-label in this context.

Gastrocolic Reflex — Physiology

• Afferent limb: gastric distension, mediated via the parasympathetic nervous system
• Efferent limb: increased colonic motility, mediated by the hormones CCK and gastrin

Management Contexts

1. Harnessing the Reflex — Bowel Training (Constipation / Fecal Incontinence)

• Suppositories or enemas (glycerin, bisacodyl) timed to coincide with the postprandial window
• Increased dietary fiber (20–35 g/day) and adequate fluid intake
• Physical activity (Kegel exercises, general exercise)
• Regular toileting schedules — particularly effective in institutionalized elderly patients with overflow incontinence from fecal impaction
• For spinal cord injury patients with a diminished gastrocolic reflex: stool softeners, laxatives, digital anal stimulation (relaxes puborectalis), manual evacuation, enemas, and anterior sacral root stimulators; colostomy may be considered for quality-of-life improvement — Yamada's Textbook of Gastroenterology; Berek & Novak's Gynecology

2. Attenuating an Exaggerated Reflex — IBS-D and Postprandial Urgency

• Dietary modification: Low-fat meals reduce the colonic motor stimulus (fat is the most potent activator)
• Low-FODMAP diet: reduces fermentable substrate and gas-driven colonic stimulation
• 5-HT3 antagonists (e.g., alosetron, ondansetron): attenuate the 5-HT3-mediated vagal component of the gastrocolic response
• Antispasmodics (e.g., hyoscine/dicyclomine): reduce colonic smooth muscle reactivity to the reflex
• Loperamide: slows colonic transit and reduces urgency, especially useful for predictable postprandial diarrhea (can be taken prophylactically before meals)
• Tricyclic antidepressants (TCAs) at low doses: reduce visceral hypersensitivity
• Psychological/behavioral approaches: biofeedback, relaxation techniques, and behavioral modification are useful adjuncts — Sleisenger & Fordtran's; Berek & Novak's

3. Impaired Gastrocolic Reflex — Neurological Conditions

• Diabetes mellitus (autonomic neuropathy) — contributes to slow colonic transit and constipation
• Spinal cord injury (SCI) — elimination of supraspinal modulation
• Multiple sclerosis

• Stimulant laxatives (bisacodyl, senna) to directly trigger HAPCs via mucosal nerve activation
• Osmotic laxatives (PEG, lactulose) for softening and transit promotion
• Cholinergic agents (prucalopride as a 5-HT4 agonist) to stimulate enteric nervous system propulsion
• Digital rectal stimulation and suppositories to initiate defecation
• Loperamide or codeine phosphate judiciously in MS-associated diarrhea — Yamada's; Sleisenger & Fordtran's

Summary Table

Depression in CKD: Management with Anhedonia and Reduced Cognition

Epidemiology and Clinical Context

Symptom-Specific Considerations

Anhedonia

Cognitive Impairment

Management Framework

Step 1 — Non-Pharmacological (First-Line, Especially Mild–Moderate)

• Cognitive-Behavioural Therapy (CBT) — demonstrated efficacy in ESKD patients; first-line for mild-to-moderate depression. Adapt for cognitive limitations (shorter sessions, written summaries, caregiver involvement)
• Interpersonal therapy (IPT) — addresses grief, role transitions, and isolation common in dialysis patients
• Exercise rehabilitation — improves both mood and cognitive performance in CKD
• Social support and isolation screening — depression is strongly associated with social isolation in this population — Brenner & Rector's

Note: cognitive impairment reduces feasibility and efficacy of standard psychotherapy protocols — simplification and caregiver inclusion are necessary adaptations.

Step 2 — Pharmacological Treatment

Sertraline is the most evidence-supported choice in CKD.

• Bupropion (norepinephrine-dopamine reuptake inhibitor): targets dopamine pathways directly relevant to anhedonia. Use with dose reduction in CKD. Caution: increased seizure risk — particularly relevant in dialysis patients who are already at elevated seizure risk due to uremia; avoid in those with history of seizures or electrolyte disturbances
• Mirtazapine (NaSSA): no dose adjustment needed for eGFR 10–50 mg/min; use at 15–45 mg/day. Benefits: appetite stimulation (counters protein-energy wasting common in CKD), sedation (helps insomnia), antipruritic properties. Has been used to treat renal failure-associated pruritus. No formal efficacy data in CKD depression specifically, but widely used.
• Pramipexole (dopamine agonist) augmentation: used off-label as an adjunct to SSRIs in treatment-resistant depression with prominent anhedonia. Has demonstrated efficacy in MDD and bipolar depression; better tolerated when added to an established SSRI than initiated concurrently. Relevant given dopamine's central role in anhedonia — Kaplan & Sadock's

• Treating the depression itself often partially improves cognition
• Avoid agents that worsen cognition: TCAs and MAOIs are contraindicated in CKD — anticholinergic effects, orthostatic hypotension, prolonged QTc, arrhythmia risk, and CNS toxicity
• Duloxetine (SNRI): useful if comorbid neuropathic pain; reduce dose interval to 48-hourly in dialysis patients; not recommended if CrCl <30 mL/min per US labeling (off-label use)
• Venlafaxine: reduce dose by 25–50% if eGFR 10–70; reduce by 50% on dialysis

• TCAs (nortriptyline, amitriptyline): not recommended for older patients with CKD due to cardiotoxicity, anticholinergic burden, and cognitive worsening
• MAOIs: avoid in all CKD patients
• Fluoxetine: long half-life makes accumulation risk higher; use alternate-day dosing or low doses if eGFR <20 — Brenner & Rector's Table 84.4

Practical Dosing Summary (Brenner & Rector's The Kidney, Table 84.4)

Monitoring

• Depression scales adapted for CKD (PHQ-9, BDI, HADS) — note that somatic symptoms of CKD (fatigue, sleep disturbance, anorexia) overlap with depressive symptoms and inflate scores
• Monitor for hyponatremia (SIADH) with SSRIs — already a risk in CKD
• Monitor QTc — citalopram/escitalopram carry QT risk at higher doses
• Monitor bleeding risk — SSRIs inhibit platelet serotonin uptake; important in dialysis patients on anticoagulation
• Re-evaluate cognition at 6–8 weeks as depression treatment takes effect

Management of Post-TBI Neuropsychiatric Syndrome with Frontal Lobe Dysfunction

Clinical Synthesis

Assessment Framework

1. Neuropsychological evaluation — formal battery covering attention, memory, executive function, visuospatial abilities, language, and processing speed; documents baseline and guides targeted rehabilitation
2. Neuroimaging — MRI brain (FLAIR, susceptibility-weighted) to assess extent of frontal parenchymal damage, encephalomalacia, white matter changes
3. EEG — post-traumatic epilepsy occurs in a significant proportion; seizure activity can mimic or worsen behavioral symptoms
4. Screening for comorbid conditions — depression (PHQ-9), PTSD, sleep disturbance (highly prevalent post-TBI; poor sleep worsens cognition and irritability), thyroid function, anaemia
5. Functional assessment — ADL/IADL capacity, caregiver burden scale

I. Non-Pharmacological Management (Cornerstone)

A. Cognitive Rehabilitation

B. Behavioral Management of Irritability, Lability, Wandering

• Reinforce desired behaviors; ignore or minimally respond to undesired behaviors
• Use distraction and redirection (validate emotion → join behavior → distract → redirect — Sutor's multistep model)
• Offer structured choices ("Would you like to walk or sit?")
• Acknowledge emotions even when the rationale is unclear
• Assess and treat unmet acute needs (pain, UTI, constipation) — all provoke behavioral deterioration

• Psychoeducation — explain frontal lobe disinhibition as a neurological phenomenon, not voluntary behavior; reduces caregiver distress and expressed emotion
• Caregiver psychotherapy, support groups
• Modify expectations of recovery
• Respite care

• Bed/door alarms
• Limit access to safety hazards (keys, stairs, exits)
• Reduce stimulation — noise, multiple simultaneous requests, crowding
• Increase structure and predictability of daily routine
• Use of familiar personal belongings to reduce confusion and agitation

C. Psychotherapy

• Cognitive-Behavioral Therapy (CBT) — for depression, anxiety, and irritability; must be adapted for cognitive limitations (shorter sessions, written aids, simplified homework, caregiver inclusion)
• Behavioral activation — for apathy and withdrawal
• Problem-solving therapy (PST) — targets executive dysfunction and frustration-based aggression
• Acceptance and Commitment Therapy (ACT) — for adjustment to functional changes
• CBT-I — if comorbid insomnia is present (improves cognition and mood)

II. Pharmacological Management

General Principles in Post-TBI Pharmacology

• Avoid drugs that lower the seizure threshold (high risk post-craniotomy)
• Avoid anticholinergic agents (worsen cognition)
• Avoid benzodiazepines (worsen cognition, disinhibition, fall risk)
• Start low, titrate slowly
• Treat identified comorbid disorders (depression, PTSD, seizures) specifically

A. Cognitive Enhancement (Attention, Memory, Executive Function)

• Improves attention, information processing speed, cognitive fatigue, and depression following TBI — small RCT evidence
• Targets dopaminergic and noradrenergic deficits in the frontal lobes (the core neurochemical disruption after TBI)
• Dose: start 5 mg BD, titrate to 10–20 mg BD; use caution re: seizure threshold and cardiovascular monitoring
• First choice for cognitive symptoms in post-TBI frontal syndrome

• Strongest evidence base in post-TBI rehabilitation. Acts as an NMDA antagonist and indirect dopamine agonist — increases presynaptic DA release and blocks reuptake, activating nigrostriatal, mesolimbic, and frontostriatal circuits
• A landmark RCT of 184 minimally conscious TBI patients showed significantly faster recovery vs. placebo at 4 weeks
• Demonstrated improvements in: arousal, attention span, learning, processing speed, agitation, aggression, mood lability, apathy, amotivation, and perseveration — especially relevant to this patient's profile
• Clinical effects can be seen within days to a week
• Dose: 100 mg BD, titrated to 200–400 mg/day
• Notably, amantadine did not increase seizure risk in TBI populations despite theoretical concern
• Strongest single pharmacological option for this patient's multi-symptom frontal syndrome — Kaplan & Sadock's

• Used for fatigue and cognitive dysfunction post-TBI; meta-analysis supports augmentation for fatigue and depression; less evidence for core cognitive domains

B. Behavioral Symptoms (Irritability, Affective Lability, Aggression)

• Target irritability, affective lability, pathological crying/laughing (PLC), and depression
• Sertraline 25–50 mg/day (most studied in TBI), escitalopram, citalopram
• For Pathological Laughing and Crying specifically: SSRIs are first-line; response can be rapid at low doses
• Alternative for PLC: Dextromethorphan/quinidine (Nuedexta) — effective but expensive

• Valproate (sodium valproate): addresses affective lability, mood dysregulation, and aggression; has the added benefit of seizure prophylaxis; consider first-choice anticonvulsant-mood stabiliser given dual utility
• Carbamazepine: used for irritability and aggression post-TBI (an RCT showed efficacy for irritability and aggression); also provides seizure cover — but recent RCTs of up to 400 mg/day for post-TBI neuropsychiatric symptoms had mixed results; useful second-line
• Lamotrigine: role in post-TBI bipolar disorder (limited data — case reports only)
• Avoid phenytoin (worsens cognition)

• Quetiapine or olanzapine — case report-level evidence for behavioral dyscontrol and psychosis post-TBI; use cautiously (sedation worsens cognition)
• Risperidone — listed as a pharmacological option for behavioral dyscontrol
• Reserve for severe, refractory cases given cognitive side-effect profile

• Effective for episodic aggression and irritability unresponsive to other treatments; mechanism via adrenergic modulation
• Listed in drug intervention boxes for aggressive behavior and episodic dyscontrol — Bradley & Daroff's

• Option for aggressive behavior and episodic dyscontrol, especially if bipolar-spectrum lability
• Requires careful monitoring; narrow therapeutic index

C. For Depression (Comorbid — Common Post-TBI)

• SSRIs remain first-line despite inconclusive sertraline RCTs in TBI (sample sizes were small)
• Escitalopram, citalopram, fluoxetine are reasonable alternatives
• Methylphenidate benefits both depression and cognitive symptoms simultaneously — dual advantage
• Bupropion: prodopaminergic, targets anhedonia/motivation; lowers seizure threshold — use extended-release formulation at low dose with monitoring; not absolutely contraindicated
• ECT: not contraindicated; considered for treatment-resistant post-TBI depression; use low-energy, brief-pulse, non-dominant unilateral; 2–5 day intervals
• rTMS: meta-analysis supports positive effect on post-TBI depression

D. Sleep Management

• CBT-I as first-line; avoid benzodiazepines
• Melatonin or low-dose mirtazapine (sedating, appetite stimulation, no seizure threshold reduction); trazodone as an alternative

III. Summary Drug Selection Matrix for This Patient

IV. Neurosurgical and Medical Follow-up

• Cranioplasty — bilateral fronto-parietal bony flap: monitor for sinking flap syndrome (paradoxical herniation); elective cranioplasty may improve neurological function and CSF dynamics
• Seizure monitoring — EEG, antiepileptic treatment if indicated
• Regular neuropsychological re-testing at 6–12 monthly intervals to document trajectory

V. Psychosocial and Rehabilitative

• Vocational rehabilitation (adapted to cognitive capacity)
• Social skills training
• Family/caregiver support program — family burden from behavioral changes exceeds that from physical disability in TBI — Kaplan & Sadock's
• Community reintegration program
• Occupational therapy home safety assessment (wandering risk)

Management of Fetishistic Disorder (Foot Fetish)

Diagnostic Framework

• Sexual arousal/fantasies/urges/behaviors involving a non-genital body part (feet) persist for ≥ 6 months, AND
• They cause clinically significant distress OR impairment in social, occupational, or other functioning

Critical clinical distinction: Many individuals have foot-related sexual interests without distress or harm to others — this constitutes a paraphilia (variant sexual interest), not a paraphilic disorder. Management is only indicated when the person experiences significant distress, impaired functioning, or when the behaviour is non-consensual or causes harm. — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Assessment Before Treatment

1. Detailed sexual history — onset, triggers, associated fantasies, whether non-consensual behaviour is involved
2. Distress/impairment assessment — PHQ-9, GAD-7; ask about relationship functioning and occupational impact
3. Comorbidity screening — other paraphilias (they frequently co-occur), depression, anxiety, OCD-spectrum disorders, substance use, personality disorders
4. Psychophysiological assessment — penile plethysmography (volumetric) measures arousal response to paraphilic vs. non-paraphilic stimuli; useful for diagnosis and to monitor treatment response
5. Risk stratification — is the interest ego-dystonic (distressing to the patient) or ego-syntonic? Does it involve non-consent or offending behaviour?

Treatment Framework

I. Psychological Treatments (First-Line, Most Evidence-Based)

A. Cognitive-Behavioural Therapy (CBT) — Most Supported

• Good Lives Model (GLM) — identifies the patient's core human needs (intimacy, autonomy, creativity) and helps them meet these through prosocial, non-offending pathways
• Risk-Need-Responsivity (RNR) Model — targets dynamic risk factors empirically associated with sexual offending behaviour

B. Insight-Oriented / Psychodynamic Psychotherapy

• Helps the patient understand the developmental origins of the fetish (often linked to a person closely involved during childhood with particular associated qualities)
• Identifies daily events and emotional triggers (e.g., real or fantasised rejection) that precipitate urges
• Enhances self-esteem and capacity for adult relational attachment
• Sex therapy is a useful adjunct when the patient attempts non-paraphilic sexual activities and experiences dysfunction

C. Group Therapy

II. Pharmacological Treatment

A. SSRIs (First-Line Pharmacotherapy for Mild–Moderate Cases)

• Mechanism: Enhanced serotonergic activity reduces sexual appetite and paraphilic urge intensity; parallels efficacy in OCD (paraphilic urges share obsessive-compulsive qualities)
• Agents: Fluoxetine, sertraline, paroxetine, escitalopram
• Evidence: Mostly case reports and small series; the WFSBP (2010/2020 guidelines) notes that "results of psychotropic drug interventions are not favorable" compared to antiandrogens, but SSRIs remain first-line for milder cases due to their tolerability and low side-effect burden
• Other psychotropics — anticonvulsants, lithium, and TCAs have not been shown to be efficacious in paraphilic disorders

B. Antiandrogens / Hormonal Agents (Moderate–Severe Cases)

III. Predictors of Good Treatment Outcome

• Single paraphilia only (as in isolated foot fetishism without other paraphilias)
• Normal intelligence
• Absence of substance abuse
• Absence of antisocial personality traits
• Presence of a successful adult attachment relationship

Paraphilic disorders remain significant treatment challenges even under favourable conditions. — Kaplan & Sadock's Synopsis

IV. When No Treatment Is Needed

• Causes no distress to the individual
• Involves only consenting adult partners
• Does not impair social, occupational, or relational functioning

Summary Algorithm

Foot fetish interest
       ↓
Distress / impairment / non-consent?
    No → Psychoeducation only
    Yes ↓
Assess severity
    Mild (ego-dystonic distress only)
        → CBT + Insight therapy ± SSRI
    Moderate (functional impairment)
        → CBT + SSRI (fluoxetine/sertraline)
    Severe / high-risk / non-consensual
        → CBT + Antiandrogen (MPA/CPA) ± GnRH agonist
        → Consider forensic/legal involvement if offending behaviour present

Laboratory Investigations for Fetishistic Disorder

I. Etiological / Diagnostic Investigations

A. Hormonal Profile

B. Neurological Investigations

C. Chromosomal / Genetic Studies

• Karyotype — 24% of paraphilic patients in investigational series had chromosomal abnormalities; relevant when developmental features (intellectual disability, dysmorphism, neurodevelopmental disorder) are also present

D. General Psychiatric Screening

E. Psychophysiological Test

• Penile plethysmography (PPG) / Penile volumetric assessment — measures penile tumescence in response to paraphilic and non-paraphilic stimuli
• Useful for confirming the diagnosis, quantifying the degree of paraphilic arousal, and monitoring treatment response
• Important limitation: some individuals can voluntarily suppress erectile responses, reducing diagnostic validity — Kaplan & Sadock's Synopsis

II. Baseline Investigations Before Pharmacotherapy

Before SSRIs

Before Antiandrogens (MPA / CPA / GnRH Agonists)

III. Monitoring During Treatment

Summary Table

1. NAFLD / MASH (Metabolic-Associated Steatohepatitis)

Key principle: Pharmacotherapy is indicated for biopsy-proven NASH with significant fibrosis (F2–F3). Patients with simple steatosis without inflammation or fibrosis should not receive liver-specific drug therapy — lifestyle modification is the intervention. — Harrison's Principles of Internal Medicine 22E

Approved / Evidence-Based Agents

GLP-1 Receptor Agonists (Preferred Emerging Agents)

GLP-1RAs have largely superseded pioglitazone in clinical practice due to their additional benefits (weight loss, glycaemic control, cardiovascular mortality reduction). — Harrison's

SGLT-2 Inhibitors

• Empagliflozin, dapagliflozin, canagliflozin: improve liver aminotransferases and quantitative hepatic steatosis; histologic endpoint data are pending. Benefit for MASH under study.

Metabolic Comorbidity Drugs (Indirect Benefit)

Agents NOT Recommended

• Ursodeoxycholic acid (UDCA) — no benefit in NASH in RCTs
• Orlistat, pentoxifylline — insufficient evidence

2. Bloating

Bloating is often multifactorial — intestinal gas accumulation, visceral hypersensitivity, dysmotility, or SIBO. Treatment should target the underlying mechanism. — Sleisenger & Fordtran's; Harrison's

Step 1 — Lifestyle Modifications (Non-pharmacological)

• Avoid gas-producing foods, carbonated beverages, chewing gum, straws
• Reduce fructose, lactose, and other fermentable carbohydrates (low-FODMAP diet)
• Eat slowly; don't swallow air

Step 2 — Pharmacological

3. Acidity (GERD / Functional Dyspepsia)

Step-up approach: lifestyle → antacids → H2RAs → PPIs → H. pylori eradication (if positive) → prokinetics or neuromodulators for refractory cases. — Harrison's; Yamada's Textbook of Gastroenterology

Step 1 — Antacids (Mild / On-Demand)

Step 2 — H2 Receptor Antagonists (Mild–Moderate GERD / Dyspepsia)

H2RAs have a marked but time-limited reduction in gastric acidity; tolerance develops with daily use. Useful for mild-moderate GERD and nocturnal acid breakthrough on PPIs. — Katzung's

Step 3 — Proton Pump Inhibitors (Moderate–Severe GERD, Erosive Oesophagitis, NSAID-related)

• C. difficile infection, SIBO, microscopic colitis
• Nutrient deficiencies: Vitamin B12, iron, calcium, magnesium
• Bone demineralisation / fracture risk
• Interstitial nephritis
• Impaired clopidogrel absorption

Many patients started on a PPI can be stepped down to H2RA or on-demand use. Normal acid exposure on 96-hour esophageal pH testing predicts successful PPI withdrawal. — Harrison's

Step 4 — Vonoprazan (Potassium-Competitive Acid Blocker)

• More potent and faster-acting than PPIs; recently FDA-approved for erosive oesophagitis
• Not dependent on food intake for activation
• Useful for PPI-refractory cases

Step 5 — H. pylori Eradication (if H. pylori positive)

• Triple therapy: PPI + clarithromycin + amoxicillin × 14 days (or metronidazole if penicillin allergy)
• Quadruple therapy if local clarithromycin resistance is high: PPI + bismuth + metronidazole + tetracycline × 14 days
• 9% risk reduction in functional dyspepsia with eradication (statistically significant)

Step 6 — Prokinetics (Postprandial Distress Syndrome subtype, Gastroparesis)

Step 7 — Centrally Acting Neuromodulators (Refractory Functional Dyspepsia/Heartburn)

4. Fatigue

Fatigue is a symptom, not a diagnosis. Always investigate and treat reversible causes first (anaemia, hypothyroidism, diabetes, sleep disorder, depression, B12 deficiency, adrenal insufficiency). Pharmacological management targets the underlying aetiology.

Step 1 — Treat Reversible / Organic Causes

Step 2 — Symptomatic Pharmacotherapy (When No Reversible Cause)

CBT + Graded Exercise Therapy (GET) remain the most evidence-based interventions for CFS/ME, with modest but statistically significant benefit from RCTs. Pharmacological treatment is adjunctive. — Goldman-Cecil Medicine; Swanson's Family Medicine

Summary: Common Pharmacological Threads